Product Description
A substance used to detect prostate cancer. It contains a monoclonal antibody that binds to prostate cells, linked to a substance that can bind radioisotopes. Capromab pendetide is combined with indium 111 and injected into the body. A gamma camera (a special camera that detects radioactivity) is used to find prostate cancer cells in the body. Capromab pendetide is a type of immunoconjugate. Also called ProstaScint. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/capromab-pendetide)
Mechanisms of Action: PSMA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | Canada | Germany | Ireland | Italy
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/15/2021 |
News Article |
United States Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight to 2026 - ResearchAndMarkets.com |
|
06/17/2019 |
News Article |
Global Prostate Cancer Therapeutics Market Outlook 2015-2022 - Developing Countries Turbo Charge Future Market Growth |
|
02/06/2019 |
News Article |
Global Prostate Cancer Therapeutics Industry |